<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Myelofibrosis (MF): Management of primary MF and secondary MF</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Myelofibrosis (MF): Management of primary MF and secondary MF</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Myelofibrosis (MF): Management of primary MF and secondary MF</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ayalew Tefferi, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1167105"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Primary myelofibrosis (PMF) and secondary myelofibrosis are <em>BCR::ABL1</em>-negative myeloproliferative neoplasms that cause bone marrow fibrosis and associated clinical findings. </p><p>Patients typically experience abdominal pain/fullness from splenomegaly, symptoms related to anemia and other cytopenias, constitutional symptoms, and they may have thrombosis or bleeding, manifestations of extramedullary hematopoiesis, and/or findings related to transformation to acute myeloid leukemia. </p><p>The goals of management of myelofibrosis are to relieve symptoms, prevent complications, and prolong survival. Prognosis is generally poor.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary MF</strong> – PMF was previously called agnogenic myeloid metaplasia, myelofibrosis with myeloid metaplasia, and chronic idiopathic myelofibrosis. Most cases are associated with mutation of <em>JAK2</em>,<em> CALR</em>,<em> </em>or<em> MPL </em>genes. Some patients present with a prefibrotic form of PMF that evolves to severely symptomatic overt fibrotic MF; contemporary classification schemes distinguish between early/prefibrotic PMF and overt fibrotic PMF [<a href="#rid1">1,2</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary</strong> <strong>MF </strong>– Secondary MF refers to MF that evolves from either polycythemia vera (PV) or essential thrombocythemia (ET).</p><p></p><p>Management of PMF and secondary MF is discussed in this topic.</p><p>Clinical manifestations and diagnosis, assessment of prognosis, and pathogenesis of PMF are presented separately. (See  <a class="medical medical_review" href="/d/html/4529.html" rel="external">"Clinical manifestations and diagnosis of primary myelofibrosis"</a> and  <a class="medical medical_review" href="/d/html/104860.html" rel="external">"Prognosis of primary myelofibrosis"</a> and  <a class="medical medical_review" href="/d/html/4526.html" rel="external">"Pathogenetic mechanisms in primary myelofibrosis"</a>.)</p><p class="headingAnchor" id="H1514958074"><span class="h1">PRETREATMENT EVALUATION</span><span class="headingEndMark"> — </span>Patients with primary myelofibrosis (PMF) and secondary myelofibrosis should be evaluated clinically for related symptoms and assessed for medical fitness, including suitability for hematopoietic cell transplantation (HCT).</p><p>PMF and secondary MF must be distinguished from other conditions that are associated with marrow fibrosis, as discussed separately. (See  <a class="medical medical_review" href="/d/html/4529.html" rel="external">"Clinical manifestations and diagnosis of primary myelofibrosis", section on 'Differential diagnosis'</a>.) </p><p class="headingAnchor" id="H2285384680"><span class="h2">Clinical and laboratory testing</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>History</strong> – Duration and severity of anemia-related symptoms, prior transfusions, blood loss, and hemolysis; recurrent or severe infections; and bleeding or bruising are noted. Medications, nutritional deficiencies, kidney or thyroid dysfunction, autoimmune disorders, and other conditions that can contribute to cytopenias should be evaluated.</p><p></p><p class="bulletIndent2">We encourage use of the myeloproliferative neoplasms symptom assessment total symptom score (MPN-SAF TSS) to evaluate the symptom burden at baseline and to monitor symptom status with treatment [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Examination</strong> – Documentation of spleen and liver size, bruising, and evidence of infections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hematology</strong> – Complete blood count and differential leukocyte count</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chemistry</strong> – Serum electrolytes, glucose, blood urea nitrogen, creatinine, liver function tests, uric acid, lactate dehydrogenase</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong> – Computed tomography (CT) of abdomen and pelvis to document the size of liver and spleen</p><p></p><p class="headingAnchor" id="H1307892919"><span class="h2">Medical fitness</span><span class="headingEndMark"> — </span>We assess medical fitness by performance status and comorbidities.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Performance status</strong> – The Eastern Cooperative Oncology Group (ECOG) performance scale  (<a class="graphic graphic_table graphicRef72901" href="/d/graphic/72901.html" rel="external">table 1</a>) or Karnofsky performance scale  (<a class="graphic graphic_table graphicRef58785" href="/d/graphic/58785.html" rel="external">table 2</a>) can provide general measures of performance status. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comorbid conditions</strong> – Significant heart, lung, liver, or kidney disease can affect tolerance for treatment used for MF. We assess comorbid conditions as described for evaluating patients with acute leukemia. (See  <a class="medical medical_review" href="/d/html/4530.html" rel="external">"Acute myeloid leukemia: Management of medically unfit adults", section on 'Medical fitness'</a>.) </p><p></p><p class="bulletIndent1">For some patients, it may be helpful to obtain geriatric consultation and/or perform a more comprehensive functional assessment to evaluate fitness, as discussed separately. (See  <a class="medical medical_review" href="/d/html/2808.html" rel="external">"Comprehensive geriatric assessment for patients with cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eligibility for hematopoietic cell transplantation</strong> – We suggest referral to transplantation specialists soon after establishing the diagnosis of MF to evaluate eligibility for allogeneic HCT and to define donor options. </p><p></p><p class="bulletIndent1">Many centers limit allogeneic HCT to patients ≤70 years without major comorbid illnesses, as described separately. (See  <a class="medical medical_review" href="/d/html/16870.html" rel="external">"Determining eligibility for allogeneic hematopoietic cell transplantation"</a>.)</p><p></p><p class="headingAnchor" id="H4291602776"><span class="h1">RISK STRATIFICATION</span><span class="headingEndMark"> — </span>Treatment of MF is guided by prognosis, as assessed by clinical and/or pathologic features using a mutation-based model. </p><p class="headingAnchor" id="H936950876"><span class="h2">Prognostic models</span><span class="headingEndMark"> — </span>Commonly used prognostic models for PMF include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>GIPSS</strong> – Genetically Inspired Prognostic Scoring System (<a class="calc calc_professional" href="/d/html/121355.html" rel="external">calculator 1</a>) [<a href="#rid4">4</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MIPSS70+ v2.0</strong> – Mutation-enhanced International Prognostic Scoring System plus karyotype, version 2.0 (<a class="calc calc_professional" href="/d/html/121059.html" rel="external">calculator 2</a>) [<a href="#rid5">5</a>]</p><p></p><p>Use of other prognostic models, such as DIPSS (Dynamic International Prognostic Scoring System) [<a href="#rid6">6</a>] or DIPSS-Plus  (<a class="graphic graphic_table graphicRef105009" href="/d/graphic/105009.html" rel="external">table 3</a>) [<a href="#rid7">7</a>], is acceptable where neither cytogenetics nor molecular analysis is available. Precision and reproducibility of various models differ, and prognostic categories do not match precisely across models. There is no consensus, but further details of prognostic assessment and models are presented separately. (See  <a class="medical medical_review" href="/d/html/104860.html" rel="external">"Prognosis of primary myelofibrosis", section on 'Our preferred approach'</a>.)</p><p class="headingAnchor" id="H612567059"><span class="h2">Prognostic classification</span><span class="headingEndMark"> — </span>We classify both primary MF (PMF) and secondary MF  (<a class="graphic graphic_algorithm graphicRef120377" href="/d/graphic/120377.html" rel="external">algorithm 1</a>) as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Higher-risk PMF</strong> – Any of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>GIPSS </strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>High risk</p><p class="bulletIndent3"><span class="glyph">-</span>Intermediate (int)-2: Note that for patients classified as GIPSS int-2, we suggest re-evaluation using MIPSS70+ v2.0, as discussed separately (see  <a class="medical medical_review" href="/d/html/104860.html" rel="external">"Prognosis of primary myelofibrosis", section on 'Assessing prognosis in PMF'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MIPSS70+ v2.0</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Very high risk</p><p class="bulletIndent3"><span class="glyph">-</span>High risk</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lower-risk PMF</strong> – Any of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>GIPSS</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Low risk</p><p class="bulletIndent3"><span class="glyph">-</span>Int-1: Note that for patients classified as GIPSS int-1, we suggest re-evaluation using MIPSS70+ v2.0, as discussed separately (see  <a class="medical medical_review" href="/d/html/104860.html" rel="external">"Prognosis of primary myelofibrosis", section on 'Assessing prognosis in PMF'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MIPSS70+ v2.0</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Intermediate risk</p><p class="bulletIndent3"><span class="glyph">-</span>Low risk</p><p class="bulletIndent3"><span class="glyph">-</span>Very low risk</p><p></p><p>Where molecular and/or cytogenetic data are not available, we use DIPSS-Plus or DIPSS as follows (see  <a class="medical medical_review" href="/d/html/104860.html" rel="external">"Prognosis of primary myelofibrosis", section on 'Alternative approaches'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Higher risk</strong> – High risk and int-2 risk </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lower risk</strong> – Int-1 risk and low risk </p><p></p><p>For assessing prognosis in secondary MF, DIPSS-Plus was superior to MYSEC, a model designed to assess prognosis in secondary MF that uses only limited genetic information [<a href="#rid8">8</a>]. </p><p class="headingAnchor" id="H1718627076"><span class="h1">HIGHER-RISK MF</span><span class="headingEndMark"> — </span>Patients with higher-risk MF have a poor prognosis and are likely to have significant disease-associated symptoms. Risk stratification of primary MF (PMF)  (<a class="graphic graphic_algorithm graphicRef120377" href="/d/graphic/120377.html" rel="external">algorithm 1</a>) is discussed above. (See <a class="local">'Risk stratification'</a> above.)</p><p>Management is guided by eligibility for allogeneic hematopoietic cell transplantation (HCT). Many institutions limit allogeneic HCT to patients ≤70 years without major medical comorbidities, but criteria may vary. </p><p>Our approach is consistent with guidelines of the United States National Comprehensive Cancer Network Myelofibrosis guidelines [<a href="#rid9">9</a>] and European LeukemiaNet (ELN)/European Blood and Marrow Transplantation Group (EBMT) [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H578018087"><span class="h2">Transplant-eligible patients</span><span class="headingEndMark"> — </span>For transplant-eligible patients with higher-risk MF, we suggest allogeneic HCT rather than symptom-directed therapy  (<a class="graphic graphic_algorithm graphicRef142768" href="/d/graphic/142768.html" rel="external">algorithm 2</a>). This suggestion places greater weight on the potential for prolonged survival with transplantation than on its substantial toxicity; while symptom-directed therapy can lessen symptoms and improve quality of life, it has not been shown to prolong survival. </p><p>The decision to pursue allogeneic HCT should be made by shared decision making that weighs transplantation-associated risks against the expected survival without transplantation and is aligned with the patient's values and preferences. A donor search should be initiated soon after diagnosis of MF. Details of eligibility for allogeneic transplantation are presented separately. (See  <a class="medical medical_review" href="/d/html/16870.html" rel="external">"Determining eligibility for allogeneic hematopoietic cell transplantation"</a>.) </p><p>No randomized trials have directly compared allogeneic HCT with symptom-based management for PMF. Studies that compare approaches should be interpreted with caution because most transplantation studies are retrospective analyses of younger, highly selected patient populations [<a href="#rid11">11-19</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transplantation versus symptom-based management</strong> </p><p></p><p class="bulletIndent1">A retrospective international study reported that among 183 patients &lt;65 years with higher-risk PMF, allogeneic HCT was associated with better survival than symptom-based management [<a href="#rid20">20</a>]. Compared with symptom-based treatments, the relative risk (RR) of death was lower with transplantation for patients who had DIPSS (Dynamic International Prognostic Scoring system) high-risk score (RR 0.37 [95% CI 0.21-0.66]) and DIPSS intermediate (int)-2 score (RR 0.55 [95% CI 0.36-0.83]). There was no survival advantage for transplantation in patients with lower-risk PMF.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transplantation outcomes </strong>– Allogeneic HCT is associated with long-term survival in approximately one-half and nonrelapse mortality (NRM) in at least one-quarter of patients with PMF [<a href="#rid21">21,22</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A retrospective study of 4142 patients with MF who underwent allogeneic HCT reported 58 percent three-year overall survival (OS), 22 percent relapse, and 29 percent NRM; 23 percent of patients had extensive chronic graft-versus-host disease (GVHD) [<a href="#rid23">23</a>]. The median age was 59 years, and nearly one-half of patients received grafts from matched unrelated donors.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Carefully selected older patients can have good outcomes with allogeneic HCT. A study of 556 patients ≥65 years who were transplanted for MF reported 40 percent five-year OS, 37 percent NRM, and 25 percent relapse [<a href="#rid24">24</a>]. A retrospective study of 30 patients (median 65 years; range 60 to 78 years) reported 45 percent three-year OS and 40 percent progression-free survival (PFS), with 13 percent day 100 mortality; most received low-intensity conditioning [<a href="#rid25">25</a>].</p><p></p><p class="headingAnchor" id="H1403870242"><span class="h3">Pretransplant spleen management</span><span class="headingEndMark"> — </span>We attempt to control massive splenomegaly (eg, &gt;15 cm below the costal margin) prior to transplantation. No studies have prospectively compared approaches for controlling massive splenomegaly before transplantation, and the preferred method varies among experts. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ruxolitinib</strong> – Among 551 patients who underwent allogeneic HCT for MF, 277 received pretransplant <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a> [<a href="#rid26">26</a>]. There was no difference in NRM based on use of pretransplant ruxolitinib (22 percent for both cohorts), but day 45 neutrophil engraftment was higher in ruxolitinib-treated patients (94 versus 85 percent). Patients with an ongoing spleen response to ruxolitinib at transplantation had better two-year event-free survival (EFS; 69 versus 54 percent) and lower risk of relapse (8 versus 19 percent).</p><p></p><p class="bulletIndent1">Other studies also suggest that pretransplant exposure to <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a> is safe [<a href="#rid27">27-32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Splenectomy </strong>– Pretransplant splenectomy was not associated with a survival difference among 1195 patients who underwent allogeneic HCT for PMF [<a href="#rid33">33</a>]. Splenectomy in 202 patients was associated with lower NRM (hazard ratio [HR] 0.64 [95% CI 0.44-0.93]) but increased risk of relapse (HR 1.43 [95% CI 1.01-2.02]); as a result, there was no difference in survival. However, OS was increased in patients who were splenectomized for massive splenomegaly (palpable spleen length ≥15 cm; HR 0.44 [95% CI 0.28-0.69]).</p><p></p><p class="bulletIndent1">There was no difference in survival, NRM, or relapse based on pretransplant splenectomy among 85 consecutive patients who were transplanted for MF [<a href="#rid34">34</a>]. The 39 patients who underwent pretransplant splenectomy had faster hematologic recovery, but one-half had surgical or postsurgical morbidities (mostly thrombosis or hemorrhage), including two who required intensive care. Another study reported that splenectomy could be safely performed before HCT [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiation therapy</strong> – There was no difference in survival among 17 patients who received splenic radiation therapy (RT) within three months of transplantation compared with 48 unirradiated patients who underwent lower-intensity conditioning allogeneic HCT for MF, but platelet engraftment was slower in the RT group [<a href="#rid36">36</a>]. </p><p></p><p class="bulletIndent1">Splenectomy and radiation therapy to control symptomatic splenomegaly are discussed below. (See <a class="local">'Splenectomy/splenic irradiation'</a> below.)</p><p></p><p class="headingAnchor" id="H2682451373"><span class="h3">Conditioning regimen</span><span class="headingEndMark"> — </span>Patient age may influence the choice of conditioning regimen. </p><p>Myeloablative conditioning (MAC) is generally preferred for patients ≤65 years, while reduced intensity conditioning (RIC) or nonmyeloablative (NMA) conditioning are generally used to lessen morbidity for older patients (eg, &gt;65 years). (See  <a class="medical medical_review" href="/d/html/3557.html" rel="external">"Preparative regimens for hematopoietic cell transplantation"</a>.)</p><p>No prospective studies have directly compared conditioning regimens, but compared with MAC, RIC is generally associated with less NRM and more relapses.</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 2224 patients who underwent allogeneic HCT for MF, outcomes were similar for 781 patients who received MAC compared with 1443 who received RIC [<a href="#rid37">37</a>]. Although patients receiving MAC were younger (median 53 versus 58 years), outcomes were similar, including five-year OS (53 versus 51 percent), five-year NRM (35 versus 34 percent), time to engraftment, and grade 2 to 4 acute GVHD. Compared with MAC, there were trends toward higher rates of five-year relapse (23 versus 20 percent) and extensive chronic GVHD (31 versus 27 percent) with RIC.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A multicenter study of 233 patients who underwent RIC allogeneic HCT reported 47 percent five-year OS and 27 percent five-year PFS; rates of NRM and relapse/progression at five years were 24 and 48 percent, respectively [<a href="#rid38">38</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a multicenter study of 103 patients who underwent RIC allogeneic HCT, five-year OS was 67 percent and five-year EFS was 51 percent; one-year NRM was 16 percent, and the three-year cumulative rate of relapse was 22 percent [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other studies have reported similar outcomes with allogeneic HCT for MF [<a href="#rid25">25,38-57</a>]. </p><p></p><p class="headingAnchor" id="H3251910991"><span class="h3">Graft source</span><span class="headingEndMark"> — </span>Transplantation outcomes may be influenced by the stem cell source. </p><p>Grafts from a matched related donor (MRD; ie, human leukocyte antigen [HLA]-matched sibling) or matched unrelated donor (MUD) are preferred, but haploidentical family members or umbilical cord blood are acceptable alternative donor sources. </p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 289 patients who were transplanted for MF, rates of five-year OS were 37, 40, and 30 percent for HLA-matched sibling donors, other HLA-matched related donors, and MUDs, respectively; corresponding disease-free survival rates were 33, 22, and 27 percent [<a href="#rid58">58</a>]. NRM was highest for MUDs (50 versus 35 and 38 percent for sibling and other related donors).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Haploidentical donor grafts have been used successfully in allogeneic HCT for PMF, with outcomes that were similar to those with matched donor sources [<a href="#rid59">59</a>]. </p><p></p><p>Despite severely fibrotic marrow, engraftment is generally not a problem in most patients with MF. A registry-based study reported engraftment in 90 percent of transplanted patients [<a href="#rid58">58</a>]. Another study reported no significant difference in engraftment parameters for 33 patients transplanted for severe MF compared with 33 matched controls without MF [<a href="#rid60">60</a>].</p><p>Alternative graft sources, including mismatched MUDs, haploidentical family members, or umbilical cord blood, are discussed separately. (See  <a class="medical medical_review" href="/d/html/3535.html" rel="external">"Donor selection for hematopoietic cell transplantation"</a>.)</p><p class="headingAnchor" id="H2870100010"><span class="h2">Ineligible for transplantation</span><span class="headingEndMark"> — </span>Preferred management for patients who are not eligible for transplantation is guided by the nature and severity of symptoms.</p><p class="headingAnchor" id="H130524866"><span class="h3">Asymptomatic higher-risk patients</span><span class="headingEndMark"> — </span>For patients with no significant symptoms related to MF, we suggest observation while monitoring for development of symptoms rather than initiating treatment.</p><p>There is no evidence that treatment of asymptomatic patients alters the natural history of higher-risk MF, and observation avoids adverse effects (AEs) associated with treatment.</p><p>For patients who subsequently develop symptoms, management is guided by the nature of the symptoms, as described in the sections that follow.</p><p class="headingAnchor" id="H3248592337"><span class="h3">Anemia only</span><span class="headingEndMark"> — </span>For patients with anemia but no symptomatic splenomegaly or constitutional symptoms, we suggest red blood cell (RBC) transfusions and adjunctive methods to lessen transfusion requirements  (<a class="graphic graphic_algorithm graphicRef142768" href="/d/graphic/142768.html" rel="external">algorithm 2</a>), rather than initial treatment with a Janus kinase inhibitor (JAKi), to avoid JAKi toxicity.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transfusions</strong> – RBC transfusions provide prompt relief of symptomatic anemia and can improve quality of life. However, chronic transfusion therapy may be associated with fluid overload, transfusion reactions, and/or alloimmunization, and heavily transfused patients may develop iron overload.</p><p></p><p class="bulletIndent1">The threshold for transfusion varies with age, symptoms, and medical comorbidities. Although there is no consensus, many centers transfuse asymptomatic patients with hemoglobin ≤8 g/dL, especially to prevent complications in patients with significant cardiovascular, pulmonary, or neurologic comorbidities. (See  <a class="medical medical_review" href="/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults"</a>.) </p><p></p><p>Because most patients with MF require ongoing RBC transfusions, we use adjunctive methods to reduce transfusion needs. There is no consensus, but acceptable choices include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Danazol</strong> – <a class="drug drug_general" data-topicid="9321" href="/d/drug information/9321.html" rel="external">Danazol</a> is a synthetic androgen that improves anemia in one-third of patients with PMF [<a href="#rid61">61-64</a>]. </p><p></p><p class="bulletIndent1">We begin with <a class="drug drug_general" data-topicid="9321" href="/d/drug information/9321.html" rel="external">danazol</a> 200 mg twice daily, but the dose can be increased to 400 mg twice daily, as tolerated. Treatment should continue for at least three months; in responsive patients, the dose can be tapered to the minimum effective dose after six months. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9321" href="/d/drug information/9321.html" rel="external">Danazol</a> is generally well tolerated, but patients may have an increase in liver enzymes (which may improve with dose reduction), headache, or increased muscle mass. The packaging label for danazol carries warnings regarding effects in pregnancy, severe thromboembolic events, and intracranial hypertension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythropoiesis-stimulating agents</strong> – The erythropoiesis-stimulating agents (ESAs), <a class="drug drug_general" data-topicid="9410" href="/d/drug information/9410.html" rel="external">epoetin alfa</a> and <a class="drug drug_general" data-topicid="8662" href="/d/drug information/8662.html" rel="external">darbepoetin alfa</a>, have only modest benefits for patients with MF.</p><p></p><p class="bulletIndent1">ESAs generally do not significantly alleviate anemia associated with MF [<a href="#rid65">65-68</a>]. Most reported responses to ESAs are in patients with PMF who were not requiring transfusion support and/or those with low serum erythropoietin levels [<a href="#rid69">69-71</a>].</p><p></p><p class="bulletIndent1">Administration and AEs of ESAs are discussed separately. (See  <a class="medical medical_review" href="/d/html/15776.html" rel="external">"Myelodysplastic syndromes/neoplasms (MDS): Management of hematologic complications in lower-risk MDS", section on 'Anemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other options</strong> – For patients whose anemia-related symptoms and transfusion requirements do not respond adequately to <a class="drug drug_general" data-topicid="9321" href="/d/drug information/9321.html" rel="external">danazol</a> or ESAs, one of the following options may be beneficial: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lenalidomide</strong><strong> plus </strong><strong>prednisone</strong> – <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">Lenalidomide</a> (various doses and schedules) plus <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> has improved anemia in one-quarter to one-third of patients and may also reduce spleen size [<a href="#rid72">72-74</a>]. We generally reserve the use of lenalidomide plus prednisone for patients with PMF who have both anemia and evidence of progressive myeloproliferation (eg, splenomegaly). The label for lenalidomide carries warnings regarding severe congenital anomalies, hematologic toxicity, and thromboembolic events.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thalidomide</strong><strong> plus </strong><strong>prednisone</strong> – <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">Thalidomide</a> 50 mg/day orally plus <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (beginning at 0.5 mg/kg orally per day and tapering over a period of three months) can achieve a response in approximately one-third of patients [<a href="#rid75">75-77</a>]. Thalidomide is associated with drowsiness, constipation, fatigue, paresthesias, neutropenia, and thrombosis. The label for thalidomide carries warnings regarding severe congenital anomalies and thromboembolic events.</p><p></p><p class="bulletIndent2">Precautions regarding the use of <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a> and <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> are discussed separately. (See  <a class="medical medical_review" href="/d/html/2794.html" rel="external">"Overview of angiogenesis inhibitors", section on 'Immunomodulatory drugs (IMiDs)'</a> and  <a class="medical medical_review" href="/d/html/1332.html" rel="external">"Multiple myeloma: Prevention of venous thromboembolism"</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="126108" href="/d/drug information/126108.html" rel="external">Luspatercept</a>, a transforming growth factor (TGF)-beta antagonist that can reduce transfusion dependence in patients with lower-risk myelodysplastic syndromes/neoplasms (MDS) and thalassemia, is under investigation for management of anemia in patients with MF. Luspatercept is not currently approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for treatment of MF-associated anemia. Treatment with luspatercept is discussed separately. (See  <a class="medical medical_review" href="/d/html/15776.html" rel="external">"Myelodysplastic syndromes/neoplasms (MDS): Management of hematologic complications in lower-risk MDS", section on 'Luspatercept'</a>.)</p><p></p><p>For patients with ongoing RBC transfusion needs despite the above treatments, we manage as discussed below. (See <a class="local">'Splenomegaly or other symptoms with anemia'</a> below.)</p><p class="headingAnchor" id="H3122404177"><span class="h3">Splenomegaly only</span><span class="headingEndMark"> — </span>For patients with symptomatic splenomegaly and no associated anemia, we suggest <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>  (<a class="graphic graphic_algorithm graphicRef142768" href="/d/graphic/142768.html" rel="external">algorithm 2</a>) rather than a JAKi, based on efficacy and little toxicity. </p><p><a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">Hydroxyurea</a> is generally associated with clinical improvement in one-quarter to one-half of patients with MF and is well tolerated. Although JAKi therapy can effectively reduce symptoms associated with splenomegaly, it is associated with more AEs than hydroxyurea.</p><p>Administration, toxicity, and outcomes with <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> are discussed below. (See <a class="local">'Hydroxyurea'</a> below.)</p><p>Patients who do not have an adequate response to <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> should be treated as discussed below. (See <a class="local">'Splenomegaly or other symptoms with anemia'</a> below.)</p><p class="headingAnchor" id="H994457657"><span class="h3">Splenomegaly or other symptoms with anemia</span><span class="headingEndMark"> — </span>We stratify treatment of patients with symptomatic splenomegaly and anemia according to the platelet count.</p><p class="headingAnchor" id="H1576925912"><span class="h4">Adequate platelets</span><span class="headingEndMark"> — </span>For patients with symptomatic splenomegaly, anemia, and platelets ≥50,000/microL (≥50 x 10<sup>9</sup>/L), we suggest <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a> or <a class="drug drug_general" data-topicid="142748" href="/d/drug information/142748.html" rel="external">momelotinib</a>  (<a class="graphic graphic_algorithm graphicRef142768" href="/d/graphic/142768.html" rel="external">algorithm 2</a>), rather than other agents. Ruxolitinib is a JAKi, while momelotinib is both a JAKi and an inhibitor of activin A receptor type 1 (ACVR1).</p><p>Outcomes were similar in a trial of 432 transplant-ineligible, JAKi-naïve patients with higher-risk PMF or symptomatic lower-risk PMF who were randomly assigned to <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a> versus <a class="drug drug_general" data-topicid="142748" href="/d/drug information/142748.html" rel="external">momelotinib</a> [<a href="#rid78">78</a>]. After 24 weeks of treatment, ≥35 percent spleen volume reduction (SVR) was seen in 29 percent of patients treated with ruxolitinib and 27 percent of patients treated with momelotinib. Ruxolitinib more effectively reduced symptoms (42 versus 28 percent), while more patients who received momelotinib became transfusion independent at week 24 (67 versus 49 percent). The most common grade ≥3 hematologic abnormalities in both groups were thrombocytopenia and anemia. Momelotinib was associated with grade ≥3 infections in 7 percent of patients and neuropathy in 10 percent (all grade ≤2), while ruxolitinib was associated with 3 percent grade ≥3 infections and 5 percent peripheral neuropathy (all grade ≤3). </p><p><a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">Ruxolitinib</a> is approved by the FDA and the EMA for patients with MF. <a class="drug drug_general" data-topicid="142748" href="/d/drug information/142748.html" rel="external">Momelotinib</a> is approved by the FDA for adults with intermediate- or high-risk MF with anemia.</p><p>Administration, toxicity, and outcomes of other studies with these agents are presented below. (See <a class="local">'Ruxolitinib'</a> below and <a class="local">'Momelotinib'</a> below.)</p><p class="headingAnchor" id="H3603435450"><span class="h4">&lt;50,000 platelets/microL</span><span class="headingEndMark"> — </span>For patients with symptomatic splenomegaly, anemia, and platelets &lt;50,000/microL, we suggest treatment with <a class="drug drug_general" data-topicid="135089" href="/d/drug information/135089.html" rel="external">pacritinib</a>  (<a class="graphic graphic_algorithm graphicRef142768" href="/d/graphic/142768.html" rel="external">algorithm 2</a>). </p><p><a class="drug drug_general" data-topicid="135089" href="/d/drug information/135089.html" rel="external">Pacritinib</a> was granted accelerated approval by the FDA for treatment of intermediate- or high-risk PMF or secondary MF with platelets &lt;50,000/microL. </p><p><a class="drug drug_general" data-topicid="135089" href="/d/drug information/135089.html" rel="external">Pacritinib</a> was more effective than best available therapy (BAT) for relieving symptoms in patients with MF with thrombocytopenia in the phase 3 PERSIST-2 trial [<a href="#rid79">79</a>]. Patients with higher-risk PMF or secondary MF and platelets ≤100,000/microL were randomly assigned to pacritinib 200 mg twice daily versus BAT (eg, <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a>, watchful waiting, <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>). There was no difference in OS, but pacritinib achieved better ≥35 percent SVR (22 versus 3 percent) and ≥50 percent reduction of symptom burden (32 versus 14 percent, using the myeloproliferative neoplasm [MPN] total symptom score). Hematologic and cardiovascular AEs were comparable between trial arms. An earlier, larger trial (PERSIST-1) that included a higher dose of pacritinib was suspended due to concerns over bleeding, cardiovascular events, and deaths.</p><p>Where <a class="drug drug_general" data-topicid="135089" href="/d/drug information/135089.html" rel="external">pacritinib</a> is not available, treatment with reduced doses of another JAKi may be tolerable.</p><p class="headingAnchor" id="H2422900851"><span class="h1">LOWER-RISK MF</span><span class="headingEndMark"> — </span>We treat patients with lower-risk primary MF (PMF) according to MF-associated symptoms. </p><p>Risk stratification for patients with MF  (<a class="graphic graphic_algorithm graphicRef120377" href="/d/graphic/120377.html" rel="external">algorithm 1</a>) is discussed above. (See <a class="local">'Risk stratification'</a> above.)</p><p class="headingAnchor" id="H4038129978"><span class="h2">Asymptomatic</span><span class="headingEndMark"> — </span>For asymptomatic patients with lower-risk MF, we suggest observation rather than symptom-directed therapy or allogeneic hematopoietic cell transplantation (HCT). Symptom-directed therapy has not been shown to improve survival in patients with MF, and the favorable prognosis for patients with lower-risk MF does not warrant the risks of allogeneic HCT. (See  <a class="medical medical_review" href="/d/html/104860.html" rel="external">"Prognosis of primary myelofibrosis", section on 'Assessing prognosis in PMF'</a>.)</p><p class="headingAnchor" id="H290321052"><span class="h2">Symptomatic</span><span class="headingEndMark"> — </span>For symptomatic patients with lower-risk MF, we suggest symptom-directed treatment rather than allogeneic HCT. Transplant-related morbidity and mortality outweigh the potential prolongation of survival in this group of patients, who have a generally favorable prognosis. </p><p>The choice of management is guided by the nature and severity of symptoms, as described above for patients who are ineligible for HCT  (<a class="graphic graphic_algorithm graphicRef142768" href="/d/graphic/142768.html" rel="external">algorithm 2</a>). (See <a class="local">'Ineligible for transplantation'</a> above.)</p><p>There was no survival advantage for patients transplanted for lower-risk PMF according to results from a retrospective international study [<a href="#rid20">20</a>]. For patients with DIPSS (Dynamic International Prognostic Scoring System) intermediate (int)-1 score, overall survival (OS) did not differ with symptom-based management (75 patients) compared with allogeneic HCT (38 patients). However, for patients with DIPSS-low score, OS was superior for 125 patients treated with conventional therapy compared with 22 who underwent transplantation (relative risk 5.6 [95% CI 1.7-19]).</p><p class="headingAnchor" id="H2518022679"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>Monitoring is guided by prognostic classification, treatment, and concerns of the clinician and patient.</p><p>For patients who receive symptom-directed therapy, we monitor the response to treatment, evidence of disease progression/complications, and symptom burden (using the myeloproliferative neoplasm [MPN]-10 tool [<a href="#rid3">3</a>]). </p><p>We schedule visits every three to six months or as clinically indicated. Evaluation should include a complete blood count, peripheral blood smear, lactate dehydrogenase (LDH), uric acid, and liver and renal function tests. </p><p class="bulletIndent1">For patients who are receiving treatment, further management is guided by the response to therapy:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adequate response</strong> – For patients who have a favorable response to therapy (eg, symptom relief, reduced transfusion needs), we continue treatment indefinitely (ie, until progression or intolerance).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inadequate response</strong> – For patients with an inadequate response to treatment, loss of response, or disease progression while receiving treatment, treatment can be continued or switched to another agent. We generally repeat a bone marrow examination in this setting to test for additional mutations that may herald disease progression. </p><p></p><p class="bulletIndent1">For patients receiving <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a>, the dose should be tapered to avoid a potentially dangerous rebound syndrome, as described below. (See <a class="local">'Ruxolitinib'</a> below.)</p><p></p><p class="bulletIndent1">Management of patients with an inadequate response is discussed below. (See <a class="local">'Relapsed/refractory MF'</a> below.)</p><p></p><p>Follow-up for patients who underwent allogeneic HCT is discussed separately. (See  <a class="medical medical_review" href="/d/html/14228.html" rel="external">"Long-term care of the adult hematopoietic cell transplantation survivor"</a>.)</p><p class="headingAnchor" id="H2103674949"><span class="h1">TREATMENTS</span></p><p class="headingAnchor" id="H863714337"><span class="h2">Ruxolitinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">Ruxolitinib</a> is a Janus kinase inhibitor (JAKi). <em>JAK2</em> is commonly mutated in primary MF (PMF), but ruxolitinib efficacy is independent of <em>JAK2</em> mutation status, which suggests that it may suppress symptoms and reduce splenomegaly through a more general inhibition of kinases [<a href="#rid80">80-83</a>]. (See  <a class="medical medical_review" href="/d/html/4526.html" rel="external">"Pathogenetic mechanisms in primary myelofibrosis", section on 'JAK2 mutations'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">Ruxolitinib</a> should not be used in patients with an active infection, and it should be used with caution in patients with thrombocytopenia, impaired liver or kidney function, or concurrent use of medications that are strong CYP3A4 inhibitors. Prior to initiating therapy, patients should be counseled about the risk of ruxolitinib withdrawal syndrome and screened for tuberculosis. </p><p></p><p class="bulletIndent1">The initial dose of <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a> is guided by the baseline platelet count:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>20 mg twice daily for a platelet count &gt;200,000/microL</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>15 mg twice daily for a platelet count between 100,000 and 200,000/microL</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>5 mg twice daily for a platelet count between 50,000 and &lt;100,000/microL</p><p></p><p class="bulletIndent1">Dose adjustments are required for renal and hepatic dysfunction and for patients receiving a concomitant strong CYP3A4 inhibitor  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 4</a>) or <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> [<a href="#rid84">84</a>]. The dose should be adjusted according to blood counts every two to four weeks until blood counts and doses are stabilized, and then as clinically indicated.</p><p></p><p class="bulletIndent1">All doses of <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a> should be taken as scheduled; if a dose is missed, the patient should be advised to return to the usual dosing schedule and not to take an additional dose. </p><p></p><p class="bulletIndent1">The dose of <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a> can be adjusted according to relief of symptoms.</p><p></p><p class="bulletIndent1">If there is no reduction in spleen size or symptom improvement after six months of treatment, <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a> should be discontinued on a tapering schedule. However, patients who appear to have ruxolitinib-resistant disease should be questioned carefully to assure that they are taking the medication at the recommended dose/schedule and are avoiding medications or herbal supplements that may impair efficacy (eg, concurrent treatment with a strong CYP3A4 inducer) [<a href="#rid84">84</a>]. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">Ruxolitinib</a> is approved by the US Food and Drug Administration (FDA), the European Commission, and Health Canada for treatment of disease-related splenomegaly or symptoms in adult patients with MF. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – Patients must be counseled that abrupt discontinuation of <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a> can be associated with a full relapse of disease symptoms and development of fever, hypotension, hypoxia, and other manifestations of systemic inflammatory response syndrome. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infections</strong> – <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">Ruxolitinib</a> should <strong>not</strong> be initiated in the setting of an active serious infection because of reports of serious bacterial, mycobacterial, fungal, and viral infections, which may be linked to its suppressive effect on natural killer cells and dendritic cells [<a href="#rid84">84-92</a>]. </p><p></p><p class="bulletIndent2">All patients should be screened for tuberculosis risk (eg, residence or travel in a country with high prevalence, close contact with a person with active tuberculosis, history of active or latent tuberculosis with unknown treatment status). Such patients should undergo testing for latent tuberculosis infection prior to starting <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a>, and those with active or latent tuberculosis should be managed in conjunction with a clinician with expertise in the treatment of tuberculosis. </p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">Ruxolitinib</a> may increase the risk of herpes zoster reactivation (shingles), and patients should seek early treatment if shingles is suspected. Herpes zoster vaccination should be considered. (See  <a class="medical medical_review" href="/d/html/8343.html" rel="external">"Vaccination for the prevention of shingles (herpes zoster)"</a>.)</p><p></p><p class="bulletIndent2">The <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a> label includes a warning regarding potential hepatitis B virus reactivation and rare cases of progressive multifocal leukoencephalopathy (PML) [<a href="#rid84">84</a>]. (See  <a class="medical medical_review" href="/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a> and  <a class="medical medical_review" href="/d/html/1694.html" rel="external">"Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ruxolitinib</strong><strong> withdrawal syndrome</strong> – Discontinuation of <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a> can be associated with a full relapse of disease symptoms, with clinical findings (eg, fever, hypotension, hypoxia) suggestive of the systemic inflammatory response syndrome [<a href="#rid93">93-95</a>]. </p><p></p><p class="bulletIndent2">Suspicion of <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a> withdrawal syndrome should prompt urgent treatment with systemic glucocorticoids and may also require treatment with vasopressors and resumption of ruxolitinib. We give <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 20 mg daily for seven days followed by a taper over the second week. <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">Hydroxyurea</a> or another myelosuppressive therapy may be necessary to control progressive leukocytosis or increasing blasts during withdrawal of ruxolitinib. (See  <a class="medical medical_review" href="/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults"</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">Ruxolitinib</a> can be associated with substantial weight gain, which may be due to the inhibition of JAK/STAT signaling downstream of the leptin receptor [<a href="#rid96">96</a>]. </p><p></p><p class="bulletIndent1">Drug discontinuation rates during the various reported treatment trials have ranged from 24 to 51 percent during the first year of treatment and were reported as high as 46 to 89 percent at three years [<a href="#rid93">93,97,98</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">Ruxolitinib</a> can relieve debilitating symptoms of PMF in up to one-half of patients, but it has not been shown to significantly prolong survival or reduce the risk of leukemic transformation in PMF.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>COMFORT-1 randomly assigned 309 patients with high-risk PMF to <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a> versus placebo [<a href="#rid81">81</a>]. Compared with placebo, at 24 weeks ruxolitinib was more effective for ≥35 percent spleen volume reduction (SVR; 42 versus 1 percent) and ≥50 percent improvement of the total symptom score (TSS; 46 versus 5 percent). SVR was sustained for ≥48 weeks for two-thirds of responding patients. There were 13 deaths in the ruxolitinib group versus 24 with placebo, and the rate of drug discontinuation was the same (11 percent) in both trial arms. Anemia and thrombocytopenia were the most common adverse effects (AEs) with ruxolitinib but rarely led to drug discontinuation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In COMFORT-2, 219 patients with higher-risk MF were randomly assigned to <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a> versus best available therapy (BAT) [<a href="#rid80">80</a>]. Importantly, for nearly one-half of the patients in this trial, <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> was used as BAT, even though 68 percent had already progressed on hydroxyurea. Ruxolitinib achieved ≥35 percent SVR in 28 percent of patients, compared with 5 percent with BAT; spleen reduction was maintained in 73 and 50 percent of subjects at 48 and 144 weeks of continued therapy, respectively [<a href="#rid98">98</a>]. Anemia and thrombocytopenia were common (grade 3 to 4 in 45 and 13 percent of patients, respectively) with ruxolitinib but were generally manageable, improved over time, and rarely led to treatment discontinuation. A separate analysis reported that, compared with a historical control of 350 ruxolitinib-naïve patients, 100 patients with PMF treated with ruxolitinib in COMFORT-2 had longer survival (5 versus 3.5 years); after adjusting for age and prognostic score, multivariate analysis found the survival advantage with ruxolitinib was maintained (hazard ratio [HR] 0.64, 95% CI 0.4-0.96) [<a href="#rid99">99</a>].</p><p></p><p class="headingAnchor" id="H3104982977"><span class="h2">Momelotinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="142748" href="/d/drug information/142748.html" rel="external">Momelotinib</a> is both a JAKi and an inhibitor of activin A receptor type 1 (ACVR1).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – <a class="drug drug_general" data-topicid="142748" href="/d/drug information/142748.html" rel="external">Momelotinib</a> 200 mg once daily by mouth.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="142748" href="/d/drug information/142748.html" rel="external">Momelotinib</a> is approved by the FDA for treatment of MF.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – Primarily cytopenias, infections, hepatotoxicity, cardiovascular events, thrombosis, and peripheral neuropathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – <a class="drug drug_general" data-topicid="142748" href="/d/drug information/142748.html" rel="external">Momelotinib</a> effectively achieved SVR and reduced transfusion burden and other symptoms in patients with MF and platelets ≥50,000/microL in a phase 3 trial (described above) [<a href="#rid78">78</a>]. (See <a class="local">'Adequate platelets'</a> above.) </p><p></p><p class="headingAnchor" id="H3203650574"><span class="h2">Fedratinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="122339" href="/d/drug information/122339.html" rel="external">Fedratinib</a> is a JAK2-selective kinase inhibitor that has activity against MF, but treatment is associated with serious and potentially fatal Wernicke-like encephalopathy. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Thiamine levels should be measured and repleted prior to starting <a class="drug drug_general" data-topicid="122339" href="/d/drug information/122339.html" rel="external">fedratinib</a> and should be assessed periodically during treatment to avoid serious Wernicke-like encephalopathy. Fedratinib should only be used in patients with platelet counts &gt;50,000/microL.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="122339" href="/d/drug information/122339.html" rel="external">Fedratinib</a> is administered 400 mg orally once daily, with or without food. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="122339" href="/d/drug information/122339.html" rel="external">Fedratinib</a> should not be given to patients with a platelet count ≤50,000/microL, severe liver impairment, strong or moderate CYP3A4 inducers, or dual CYP3A4 and CYP2C19 inhibitors  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 4</a>). The initial dose should be reduced for patients receiving strong CYP3A inhibitors or with severe renal impairment, and the dose should be reduced for management of fedratinib toxicity, as described below. </p><p></p><p class="bulletIndent1">If Wernicke-like encephalopathy is suspected, <a class="drug drug_general" data-topicid="122339" href="/d/drug information/122339.html" rel="external">fedratinib</a> must be discontinued immediately and parenteral thiamine given. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="122339" href="/d/drug information/122339.html" rel="external">Fedratinib</a> is approved by the FDA for treatment of higher-risk PMF in adults with platelets &gt;50,000/microL. The label has a warning about the risk of encephalopathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – Treatment may be associated with cardiovascular conditions, liver toxicity, and rare cases of severe, sometimes fatal, encephalopathy. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Encephalopathy</strong> – Serious and fatal encephalopathy, including Wernicke encephalopathy, has occurred in patients treated with <a class="drug drug_general" data-topicid="122339" href="/d/drug information/122339.html" rel="external">fedratinib</a>; serious cases were reported in 1.3 percent (8/608) of patients treated in clinical trials, and death resulted in 0.16 percent (1/608) of cases [<a href="#rid100">100</a>]. In a clinical trial (described below) that included patients treated with fedratinib 500 mg daily, encephalopathy developed in seven patients; there were no cases of encephalopathy among patients who were treated with 400 mg daily [<a href="#rid101">101</a>]. Fedratinib has also been associated with cardiovascular death, myocardial infarction, stroke, and liver toxicity in some patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Withdrawal syndrome</strong> – The risk and/or severity of a <a class="drug drug_general" data-topicid="122339" href="/d/drug information/122339.html" rel="external">fedratinib</a> withdrawal syndrome is not well defined, but we taper the dose, rather than abruptly discontinuing it, except when encephalopathy is suspected. (See  <a class="medical medical_review" href="/d/html/4818.html" rel="external">"Wernicke encephalopathy", section on 'Clinical manifestations'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – <a class="drug drug_general" data-topicid="122339" href="/d/drug information/122339.html" rel="external">Fedratinib</a> reduced splenomegaly and symptoms in more than one-third of patients in an international, double-blind, placebo-controlled trial of 289 adults with higher risk PMF, post-polycythemia vera MF, or postessential thrombocythemia MF [<a href="#rid101">101</a>]. Patients were randomly assigned to fedratinib 400 mg, fedratinib 500 mg, or placebo for ≥6 consecutive four-week cycles. SVR ≥35 percent at week 24 was achieved in 36, 40, and 1 percent of patients who received 400 mg fedratinib, 500 mg fedratinib, and placebo, respectively. Reduction of TSS by ≥50 percent at week 24 was achieved in 36, 34, and 7 percent of patients, respectively. Common AEs with fedratinib were anemia; gastrointestinal symptoms; and elevated liver transaminases, serum creatinine, and pancreatic enzymes. </p><p></p><p class="headingAnchor" id="H2081635601"><span class="h2">Pacritinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="135089" href="/d/drug information/135089.html" rel="external">Pacritinib</a> is an inhibitor of JAK2 and FMS-like tyrosine kinase 3 (FLT3) [<a href="#rid102">102</a>] that is used for treating MF in patients with baseline or treatment-emergent thrombocytopenia. Pacritinib has been associated with cardiovascular events and bleeding. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – <a class="drug drug_general" data-topicid="135089" href="/d/drug information/135089.html" rel="external">Pacritinib</a> is given 200 mg twice daily by mouth, with or without food. </p><p></p><p class="bulletIndent1">Strong CYP3A4 inhibitors or inducers are contraindicated; moderate CYP3A4 inhibitors or inducers should be avoided. <a class="drug drug_general" data-topicid="135089" href="/d/drug information/135089.html" rel="external">Pacritinib</a> should be avoided in patients with moderate or severe liver impairment or kidney disease [<a href="#rid103">103</a>]. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="135089" href="/d/drug information/135089.html" rel="external">Pacritinib</a> was granted accelerated approval by the FDA for treatment of intermediate- or high-risk PMF or secondary MF with platelets &lt;50,000/microL. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – Includes hemorrhage, diarrhea, prolonged QT interval, and thrombosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – In the phase 3 PERSIST-2 trial, <a class="drug drug_general" data-topicid="135089" href="/d/drug information/135089.html" rel="external">pacritinib</a> was more effective than BAT for SVR and reducing symptom burden in patients with MF with thrombocytopenia [<a href="#rid79">79</a>]. Patients with intermediate- or high-risk PMF or secondary MF with platelets ≤100,000/microL were randomly assigned to pacritinib 200 mg twice daily versus BAT (eg, <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a>, watchful waiting, <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>). There was no difference in overall survival (OS) between trial arms, but compared with BAT, pacritinib was more effective for ≥35 percent SVR (22 versus 3 percent), ≥50 percent reduction of TSS (32 versus 14 percent), and reducing transfusion requirements. Hematologic and cardiovascular AEs were comparable between trial arms. An earlier, larger trial (PERSIST-1) that included a higher dose of pacritinib was suspended due to concerns over bleeding and cardiovascular events and deaths.</p><p></p><p class="headingAnchor" id="H1833409978"><span class="h2">Hydroxyurea</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">Hydroxyurea</a> can relieve moderate splenomegaly and other proliferative manifestations (eg, thrombocytosis, leukocytosis, constitutional symptoms) in patients without significant anemia. </p><p><a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">Hydroxyurea</a> is also acceptable for symptom management in patients who are ineligible for allogeneic hematopoietic cell transplantation (HCT) or who are not candidates for a JAKi.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – We initiate <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> 500 to 1000 mg every other day. Note that this dose is lower than what is used for other myeloproliferative neoplasms because many patients with MF have cytopenias with limited bone marrow reserves.</p><p></p><p class="bulletIndent1">The dose should be modified based on semiweekly or weekly blood counts until doses are stabilized, and then as clinically indicated.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">Hydroxyurea</a> is not labeled for treatment of MF by the FDA or the EMA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity </strong>– Includes cytopenias, mucocutaneous ulcers, diarrhea, peripheral neuropathy, skin cancer, potential teratogenicity, and rare cases of severe (including fatal) pulmonary toxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">Hydroxyurea</a> was associated with clinical improvement or partial response in 28 percent of 69 patients with PMF [<a href="#rid104">104</a>]. In another report, 40 percent of patients with PMF treated with hydroxyurea achieved ≥50 SVR, with responses that lasted for an average of one year [<a href="#rid105">105</a>]. </p><p></p><p class="headingAnchor" id="H2522347674"><span class="h2">Splenectomy/splenic irradiation</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical splenectomy</strong> – Surgical splenectomy can relieve mechanical discomfort from marked splenomegaly, but it is associated with substantial morbidity and mortality. Splenectomy can provide relief for selected patients with recurrent splenic infarction, transfusion-dependent anemia, refractory thrombocytopenia, hypercatabolic symptoms, portal hypertension, or high-output heart failure.</p><p></p><p class="bulletIndent1">Surgical splenectomy generally provides short-term relief but is associated with approximately 10 percent surgical mortality, short-term and long-term complications (eg, intra-abdominal bleeding, subphrenic abscess, sepsis, extreme thrombocytosis, accelerated hepatomegaly, splanchnic thrombosis), and does not improve survival [<a href="#rid106">106</a>]. (See  <a class="medical medical_review" href="/d/html/117640.html" rel="external">"Elective (diagnostic or therapeutic) splenectomy"</a> and <a class="local">'Postsplenectomy thrombocytosis or hepatomegaly'</a> below.)</p><p></p><p class="bulletIndent1">In transfusion-dependent patients, it is unclear if reducing splenic sequestration with splenectomy outweighs the loss of an important site of extramedullary erythropoiesis. We generally offer surgical splenectomy <strong>only</strong> if a nonbleeding patient with MF chronically requires ≥3 units of red blood cells (RBCs) every two weeks; we consider that the spleen is not an effective source of RBC production in that setting, based on typical transfusion requirements in adults with no effective erythropoiesis (eg, severe aplastic anemia or pure red cell aplasia).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Splenic irradiation</strong> – Splenic irradiation can provide transient benefit (eg, three to six months) for patients with worsening symptoms who are poor surgical candidates, but it is often complicated by nausea and cytopenias [<a href="#rid107">107</a>]. Abscopal effects of the splenic irradiation can lead to significant myelosuppression and profound thrombocytopenia [<a href="#rid108">108</a>].</p><p></p><p class="bulletIndent1">The preferred dose and schedule vary by institution, but it is prudent to treat with small fractions (eg, 0.25 to 0.5 Gy two to four times per week), with modifications based on the clinical situation and frequent blood counts. In a series of 23 patients with PMF, most had an objective reduction in splenic size and symptomatic relief (median duration: six months), but one-third had significant cytopenias, with fatal sepsis or hemorrhage in three patients [<a href="#rid109">109</a>].</p><p></p><p class="headingAnchor" id="H181270677"><span class="h1">SPECIFIC MANAGEMENT ISSUES</span><span class="headingEndMark"> — </span>Management of other aspects of MF is described in the sections below.</p><p class="headingAnchor" id="H1604437"><span class="h2">Extramedullary hematopoiesis</span><span class="headingEndMark"> — </span>Pain or organ dysfunction from extramedullary hematopoiesis may occur in the spinal cord, peritoneal and pleural cavities, bone, liver, lung, and other organs. The presentation is similar to clinical manifestations of myeloid sarcoma, and radiation therapy is often successful in the management of symptomatic foci primary MF (PMF) [<a href="#rid110">110-114</a>]. (See  <a class="medical medical_review" href="/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia", section on 'Myeloid sarcoma'</a>.)</p><p class="headingAnchor" id="H2008634713"><span class="h2">Leukemic transformation</span><span class="headingEndMark"> — </span>Leukemic transformation is the most common cause of death in PMF [<a href="#rid115">115-117</a>]. (See  <a class="medical medical_review" href="/d/html/4529.html" rel="external">"Clinical manifestations and diagnosis of primary myelofibrosis", section on 'Transformation to acute leukemia'</a>.)</p><p>There is no standard treatment of leukemic transformation. Participation in a clinical trial is strongly encouraged. </p><p>Treatment options include intensive induction with acute myeloid leukemia (AML)-like therapy, lower-intensity treatments (eg, hypomethylating agents, <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a>), and palliative care. Some patients seek allogeneic hematopoietic cell transplantation (HCT). A decision of when and how to treat leukemic transformation is influenced by overall clinical status, fitness, institutional approach, and patient preference. (See  <a class="medical medical_review" href="/d/html/94786.html" rel="external">"Acute myeloid leukemia in adults: Overview"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intensive treatments</strong> – A prospective study that used intensive AML-like induction therapy followed by allogeneic HCT reported outcomes of 75 consecutive patients with leukemic transformation after PMF and other myeloproliferative neoplasms (MPNs) [<a href="#rid118">118</a>]. For 38 patients treated with intensive induction therapy (with or without subsequent HCT), the median survival was longer (nine versus two months) and two-year overall survival (OS) was better (26 versus 3 percent) compared with treatment with noncurative intent. Among the 17 patients who underwent allogeneic HCT, 5 remained alive and free of AML with a median OS of 47 months after initial leukemic transformation. </p><p></p><p class="bulletIndent1">Retrospective studies that utilized intensive remission induction chemotherapy for leukemic transformation described complete remission (CR) in 0 to 60 percent and a median OS of four to nine months [<a href="#rid117">117,119-124</a>]. Retrospective studies of patients who underwent allogeneic HCT after induction therapy for leukemic transformation report improved survival compared with those who did not undergo HCT [<a href="#rid119">119,121,123</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lower-intensity therapy</strong> – <a class="drug drug_general" data-topicid="8797" href="/d/drug information/8797.html" rel="external">Azacitidine</a>, <a class="drug drug_general" data-topicid="8855" href="/d/drug information/8855.html" rel="external">decitabine</a>, and Janus kinase inhibitor (JAKi) therapy have limited activity in patients with leukemic transformation who are transplant candidates. A single-institution study of six patients treated with decitabine reported a median survival &gt;9 months, reduced spleen size, and improved symptoms [<a href="#rid125">125</a>]. Treatment with azacitidine of 26 patients with leukemic transformation achieved an overall response rate of 26 percent and median OS of eight months [<a href="#rid122">122</a>]. Treatment with <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a> achieved CR in 3 of 18 patients with leukemic transformation [<a href="#rid126">126</a>].</p><p></p><p class="bulletIndent1">Management of AML with lower-intensity treatments is discussed separately. (See  <a class="medical medical_review" href="/d/html/4530.html" rel="external">"Acute myeloid leukemia: Management of medically unfit adults"</a>.)</p><p></p><p class="headingAnchor" id="H2023818744"><span class="h2">Postsplenectomy thrombocytosis or hepatomegaly</span><span class="headingEndMark"> — </span>Thrombocytosis and/or hepatomegaly are common after surgical splenectomy. A retrospective, single-institution study of 314 patients with PMF who underwent splenectomy reported postoperative platelet count &gt;10<sup>6</sup>/microL (5 percent), bleeding (14 percent), thrombosis (10 percent), and accelerated hepatomegaly (10 percent) [<a href="#rid127">127</a>]. Another study of 71 patients described massive hepatomegaly in 24 percent of patients [<a href="#rid128">128</a>].</p><p>There is no consensus management for postsplenectomy thrombocytosis and hepatomegaly. Options include platelet pheresis, <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>, or <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> [<a href="#rid129">129,130</a>]. (See  <a class="medical medical_review" href="/d/html/4486.html" rel="external">"Essential thrombocythemia: Treatment and prognosis", section on 'Acquired von Willebrand syndrome'</a> and <a class="local">'Hydroxyurea'</a> above.)</p><p>After postoperative hemostasis has been achieved, we consider short-term anticoagulation (eg, one month of therapeutic anticoagulation with low molecular weight heparin) to minimize the risk of splanchnic vein thrombosis, but this decision should be individualized.</p><p class="headingAnchor" id="H3660481360"><span class="h1">RELAPSED/REFRACTORY MF</span><span class="headingEndMark"> — </span>Management of relapsed or refractory (r/r) MF should consider severity of symptoms, prior treatments, duration of response, and patient preference. We encourage patients with r/r MF to participate in clinical trials. </p><p>For patients who remain symptomatic after symptom-based treatment, we suggest <a class="drug drug_general" data-topicid="142748" href="/d/drug information/142748.html" rel="external">momelotinib</a> or <a class="drug drug_general" data-topicid="122339" href="/d/drug information/122339.html" rel="external">fedratinib</a>, based on improved symptom control and acceptable toxicity. For patients who were previously treated with momelotinib, we treat with fedratinib.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Momelotinib</strong> – A phase 3 trial (MOMENTUM) of <a class="drug drug_general" data-topicid="142748" href="/d/drug information/142748.html" rel="external">momelotinib</a> versus <a class="drug drug_general" data-topicid="9321" href="/d/drug information/9321.html" rel="external">danazol</a> in symptomatic and anemic patients (124 with primary MF [PMF] and 71 with secondary MF) who were previously treated with a Janus kinase inhibitor (JAKi) reported similar overall survival (OS) in both trial arms, but momelotinib achieved better symptom control [<a href="#rid131">131</a>]. Compared with danazol, momelotinib achieved superior symptom reduction (≥50 percent improvement of total symptom score [TSS]; 25 versus 9 percent) and transfusion independence (31 versus 20 percent). Momelotinib was associated with less grade ≥3 anemia and similar levels of thrombocytopenia (&lt;50 x 10<sup>9</sup>/L), nonhematologic toxicity, and fatal adverse effects (AEs; 12 versus 17 percent with danazol). More patients in the danazol group discontinued treatment early.</p><p></p><p class="bulletIndent1">Another phase 3 trial (SIMPLIFY­2) reported that <a class="drug drug_general" data-topicid="142748" href="/d/drug information/142748.html" rel="external">momelotinib</a> achieved similar outcomes as best available therapy (BAT) in 156 symptomatic, ruxolitinib-treated patients [<a href="#rid132">132</a>]. Patients were randomly assigned (2:1) to momelotinib (104 patients) versus BAT (52 patients; 89 percent received <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a> and others received chemotherapy, steroids, other standard interventions, or no treatment). The trial arms achieved similar rates of ≥35 percent spleen volume reduction (SVR; 7 percent with momelotinib and 6 percent with BAT), serious AEs (35 versus 23 percent, respectively), and treatment-related mortality (6 versus 8 percent, respectively). </p><p></p><p class="bulletIndent1">Administration of <a class="drug drug_general" data-topicid="142748" href="/d/drug information/142748.html" rel="external">momelotinib</a> is discussed above. (See <a class="local">'Momelotinib'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fedratinib</strong> – In the JAKARTA2 study, nearly one-third of patients who were <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a> resistant, refractory, or intolerant had ≥35 percent SVR and ≥50 percent reduction in TSS; grade ≥3 anemia and thrombocytopenia were reported in 38 and 22 percent, respectively [<a href="#rid133">133</a>]. </p><p></p><p class="bulletIndent1">Administration of <a class="drug drug_general" data-topicid="122339" href="/d/drug information/122339.html" rel="external">fedratinib</a> is discussed above. (See <a class="local">'Fedratinib'</a> above.)</p><p></p><p class="headingAnchor" id="H145492599"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Our approach is consistent with consensus recommendations for hematopoietic cell transplantation in primary MF by the European LeukemiaNet (ELN) and European Blood and Marrow Transplantation Group (EBMT) [<a href="#rid10">10</a>] and United States National Comprehensive Cancer Network Myelofibrosis guidelines [<a href="#rid9">9</a>].</p><p>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116776.html" rel="external">"Society guideline links: Myeloproliferative neoplasms"</a>.)</p><p class="headingAnchor" id="H30"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Myelofibrosis (MF) refers to a myeloproliferative neoplasm (MPN) characterized by bone marrow fibrosis, cytopenias, constitutional symptoms, hepatosplenomegaly, and/or extramedullary hematopoiesis. Patients are at risk for premature death from disease progression, leukemic transformation, thrombohemorrhagic complications, and infections. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Primary MF</strong> – A category of <em>BCR::ABL1</em>-negative MPN</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Secondary MF</strong> – MF that arose from another type of MPN </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation </strong>– Symptoms and medical fitness are assessed prior to treatment. (See <a class="local">'Pretreatment evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk stratification</strong> – Patients are classified according to clinical features, pathologic findings, and/or mutation status  (<a class="graphic graphic_algorithm graphicRef120377" href="/d/graphic/120377.html" rel="external">algorithm 1</a>) as described above (see <a class="local">'Risk stratification'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Higher risk</strong></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lower risk</strong></p><p></p><p class="bulletIndent1">Management of MF is guided by the risk category, symptoms, and medical fitness. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Higher-risk MF, transplant-eligible patients </strong>– For patients with higher-risk MF who are eligible for transplantation, we suggest allogeneic hematopoietic cell transplantation (HCT) rather than symptom-directed therapy  (<a class="graphic graphic_algorithm graphicRef142768" href="/d/graphic/142768.html" rel="external">algorithm 2</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Transplant-eligible patients'</a> above.)</p><p></p><p class="bulletIndent1">Allogeneic HCT is generally limited to patients ≤70 years with major comorbid illnesses. Pretransplant management of symptomatic splenomegaly and selection of a conditioning regimen and graft source are discussed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Higher-risk MF,</strong> <strong>not eligible for hematopoietic cell transplantation </strong>–<strong> </strong>Management is guided by the nature and severity of symptoms.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Asymptomatic</strong> – For patients with no significant symptoms related to MF, we suggest observation while monitoring for development of symptoms rather than initiating treatment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Asymptomatic higher-risk patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anemia only</strong> – For patients with anemia only (ie, no symptomatic splenomegaly or other proliferative symptoms), we suggest transfusion therapy plus adjunctive approaches to reduce transfusion burden  (<a class="graphic graphic_algorithm graphicRef142768" href="/d/graphic/142768.html" rel="external">algorithm 2</a>) rather than a Janus kinase inhibitor (JAKi) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Examples of such approaches include <a class="drug drug_general" data-topicid="9321" href="/d/drug information/9321.html" rel="external">danazol</a> or an erythropoiesis-stimulating agent. (See <a class="local">'Anemia only'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Splenomegaly without anemia</strong> – For symptomatic splenomegaly or other proliferative symptoms without anemia, we suggest <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>  (<a class="graphic graphic_algorithm graphicRef142768" href="/d/graphic/142768.html" rel="external">algorithm 2</a>) rather than a JAKi (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Splenomegaly only'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Splenomegaly with anemia and platelets ≥50,000/microL</strong> – For symptomatic splenomegaly, anemia, and adequate platelets, we suggest <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a> or <a class="drug drug_general" data-topicid="142748" href="/d/drug information/142748.html" rel="external">momelotinib</a>  (<a class="graphic graphic_algorithm graphicRef142768" href="/d/graphic/142768.html" rel="external">algorithm 2</a>) rather than other treatments (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Adequate platelets'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Splenomegaly with anemia and platelets &lt;50,000/microL</strong> – For symptomatic splenomegaly, anemia, and low platelets, we suggest <a class="drug drug_general" data-topicid="135089" href="/d/drug information/135089.html" rel="external">pacritinib</a>  (<a class="graphic graphic_algorithm graphicRef142768" href="/d/graphic/142768.html" rel="external">algorithm 2</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'&lt;50,000 platelets/microL'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lower-risk MF</strong> – Management of patients with lower-risk MF is guided by symptoms:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Asymptomatic</strong> – For asymptomatic patients with lower-risk MF, we suggest observation rather than systemic treatments (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Asymptomatic'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Symptomatic</strong> – Management of symptomatic patients with lower-risk MF is guided by the nature of symptoms, as discussed for higher-risk patients. (See <a class="local">'Ineligible for transplantation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatments</strong> – Administration, toxicity, and outcomes with drugs used for symptom-based management of MF are discussed above. (See <a class="local">'Treatments'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Special management issues </strong>– Management of extramedullary hematopoiesis, leukemic transformation, and postsplenectomy thrombocytosis is discussed above. (See <a class="local">'Specific management issues'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapsed/refractory MF</strong> – For persistent symptoms after prior treatment, we suggest either <a class="drug drug_general" data-topicid="142748" href="/d/drug information/142748.html" rel="external">momelotinib</a> or <a class="drug drug_general" data-topicid="122339" href="/d/drug information/122339.html" rel="external">fedratinib</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>); for those with prior exposure to momelotinib, we offer fedratinib. (See <a class="local">'Relapsed/refractory MF'</a> above.)</p><p></p><p class="headingAnchor" id="H3435913291"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editors of UpToDate acknowledge the contributions of Stanley L Schrier, MD as Section Editor on this topic, his tenure as the founding Editor-in-Chief for UpToDate in Hematology, and his dedicated and longstanding involvement with the UpToDate program.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022; 140:1200.</a></li><li><a class="nounderline abstract_t">Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022; 36:1703.</a></li><li><a class="nounderline abstract_t">Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 2012; 30:4098.</a></li><li><a class="nounderline abstract_t">Tefferi A, Guglielmelli P, Nicolosi M, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia 2018; 32:1631.</a></li><li><a class="nounderline abstract_t">Tefferi A, Guglielmelli P, Lasho TL, et al. MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. J Clin Oncol 2018; 36:1769.</a></li><li><a class="nounderline abstract_t">Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115:1703.</a></li><li><a class="nounderline abstract_t">Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29:392.</a></li><li><a class="nounderline abstract_t">Shide K, Takenaka K, Kitanaka A, et al. Nationwide prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to MYSEC-PM as a survival risk model. Blood Cancer J 2023; 13:110.</a></li><li class="breakAll">National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/mpn_blocks.pdf (Accessed on November 29, 2018).</li><li><a class="nounderline abstract_t">Kröger NM, Deeg JH, Olavarria E, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia 2015; 29:2126.</a></li><li><a class="nounderline abstract_t">Guardiola P, Esperou H, Cazals-Hatem D, et al. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. French Society of Bone Marrow Transplantation. Br J Haematol 1997; 98:1004.</a></li><li><a class="nounderline abstract_t">Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102:3912.</a></li><li><a class="nounderline abstract_t">Przepiorka D, Giralt S, Khouri I, et al. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol 1998; 57:24.</a></li><li><a class="nounderline abstract_t">Singhal S, Powles R, Treleaven J, et al. Allogeneic bone marrow transplantation for primary myelofibrosis. Bone Marrow Transplant 1995; 16:743.</a></li><li><a class="nounderline abstract_t">Creemers GJ, Löwenberg B, Hagenbeek A. Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol 1992; 82:772.</a></li><li><a class="nounderline abstract_t">Benesch M, Deeg HJ. Hematopoietic cell transplantation for adult patients with myelodysplastic syndromes and myeloproliferative disorders. Mayo Clin Proc 2003; 78:981.</a></li><li><a class="nounderline abstract_t">Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999; 93:2831.</a></li><li><a class="nounderline abstract_t">Lissandre S, Bay JO, Cahn JY, et al. Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis. Bone Marrow Transplant 2011; 46:557.</a></li><li><a class="nounderline abstract_t">Visani G, Finelli C, Castelli U, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 1990; 75:4.</a></li><li><a class="nounderline abstract_t">Kröger N, Giorgino T, Scott BL, et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood 2015; 125:3347.</a></li><li><a class="nounderline abstract_t">Ali H, Bacigalupo A. 2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management. Am J Hematol 2021; 96:1532.</a></li><li><a class="nounderline abstract_t">Deeg HJ, Bredeson C, Farnia S, et al. Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups. Biol Blood Marrow Transplant 2015; 21:1883.</a></li><li><a class="nounderline abstract_t">McLornan D, Eikema DJ, Czerw T, et al. Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis. Bone Marrow Transplant 2021; 56:2160.</a></li><li><a class="nounderline abstract_t">Hernández-Boluda JC, Pereira A, Kröger N, et al. Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry. Am J Hematol 2021; 96:1186.</a></li><li><a class="nounderline abstract_t">Samuelson S, Sandmaier BM, Heslop HE, et al. Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. Br J Haematol 2011; 153:76.</a></li><li><a class="nounderline abstract_t">Kröger N, Sbianchi G, Sirait T, et al. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. Leukemia 2021; 35:3551.</a></li><li><a class="nounderline abstract_t">Robin M, Porcher R, Orvain C, et al. Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups. Bone Marrow Transplant 2021; 56:1888.</a></li><li><a class="nounderline abstract_t">Shahnaz Syed Abd Kadir S, Christopeit M, Wulf G, et al. Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis. Eur J Haematol 2018; 101:305.</a></li><li><a class="nounderline abstract_t">Stübig T, Alchalby H, Ditschkowski M, et al. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. Leukemia 2014; 28:1736.</a></li><li><a class="nounderline abstract_t">Hanif A, Hari PN, Atallah E, et al. Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms. Bone Marrow Transplant 2016; 51:617.</a></li><li><a class="nounderline abstract_t">Shanavas M, Popat U, Michaelis LC, et al. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biol Blood Marrow Transplant 2016; 22:432.</a></li><li><a class="nounderline abstract_t">Ali H, Tsai NC, Synold T, et al. Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study. Blood Adv 2022; 6:1444.</a></li><li><a class="nounderline abstract_t">Polverelli N, Mauff K, Kröger N, et al. Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). Am J Hematol 2021; 96:69.</a></li><li><a class="nounderline abstract_t">Robin M, Zine M, Chevret S, et al. The Impact of Splenectomy in Myelofibrosis Patients before Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2017; 23:958.</a></li><li><a class="nounderline abstract_t">Bossard JB, Beuscart JB, Robin M, et al. Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study. Am J Hematol 2021; 96:80.</a></li><li><a class="nounderline abstract_t">Bales JR, Kim HT, Portillo R, et al. Splenic irradiation prior to allogeneic hematopoietic cell transplantation for patients with myelofibrosis. Bone Marrow Transplant 2023; 58:459.</a></li><li><a class="nounderline abstract_t">McLornan D, Szydlo R, Koster L, et al. Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2019; 25:2167.</a></li><li><a class="nounderline abstract_t">Gupta V, Malone AK, Hari PN, et al. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2014; 20:89.</a></li><li><a class="nounderline abstract_t">Kröger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114:5264.</a></li><li><a class="nounderline abstract_t">Rondelli D, Goldberg JD, Isola L, et al. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood 2014; 124:1183.</a></li><li><a class="nounderline abstract_t">Robin M, Tabrizi R, Mohty M, et al. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Br J Haematol 2011; 152:331.</a></li><li><a class="nounderline abstract_t">Merup M, Lazarevic V, Nahi H, et al. Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J Haematol 2006; 135:367.</a></li><li><a class="nounderline abstract_t">Devine SM, Hoffman R, Verma A, et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002; 99:2255.</a></li><li><a class="nounderline abstract_t">Hessling J, Kröger N, Werner M, et al. Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 119:769.</a></li><li><a class="nounderline abstract_t">Kröger N, Zabelina T, Schieder H, et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 2005; 128:690.</a></li><li><a class="nounderline abstract_t">Rondelli D, Barosi G, Bacigalupo A, et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005; 105:4115.</a></li><li><a class="nounderline abstract_t">Bacigalupo A, Soraru M, Dominietto A, et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant 2010; 45:458.</a></li><li><a class="nounderline abstract_t">Alchalby H, Badbaran A, Zabelina T, et al. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 2010; 116:3572.</a></li><li><a class="nounderline abstract_t">Abelsson J, Merup M, Birgegård G, et al. The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. Bone Marrow Transplant 2012; 47:380.</a></li><li><a class="nounderline abstract_t">Alchalby H, Yunus DR, Zabelina T, et al. Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. Br J Haematol 2012; 157:75.</a></li><li><a class="nounderline abstract_t">Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V, et al. Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia. Am J Hematol 2007; 82:400.</a></li><li><a class="nounderline abstract_t">Benjamini O, Koren-Michowitz M, Amariglio N, et al. Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation. Leukemia 2008; 22:1961.</a></li><li><a class="nounderline abstract_t">Lussana F, Rambaldi A, Finazzi MC, et al. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2014; 99:916.</a></li><li><a class="nounderline abstract_t">Snyder DS, Palmer J, Stein AS, et al. Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Biol Blood Marrow Transplant 2006; 12:1161.</a></li><li><a class="nounderline abstract_t">Patriarca F, Bacigalupo A, Sperotto A, et al. Outcome of allogeneic stem cell transplantation following reduced-intensity conditioninig regimen in patients with idiopathic myelofibrosis: the g.I.T.m.o. Experience. Mediterr J Hematol Infect Dis 2010; 2:e2010010.</a></li><li><a class="nounderline abstract_t">Snyder DS, Palmer J, Gaal K, et al. Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis. Biol Blood Marrow Transplant 2010; 16:281.</a></li><li><a class="nounderline abstract_t">Robin M, Porcher R, Wolschke C, et al. Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis. Biol Blood Marrow Transplant 2016; 22:1206.</a></li><li><a class="nounderline abstract_t">Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010; 16:358.</a></li><li><a class="nounderline abstract_t">Raj K, Eikema DJ, McLornan DP, et al. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2019; 25:522.</a></li><li><a class="nounderline abstract_t">Soll E, Massumoto C, Clift RA, et al. Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment. Blood 1995; 86:4667.</a></li><li><a class="nounderline abstract_t">Lévy V, Bourgarit A, Delmer A, et al. Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases. Am J Hematol 1996; 53:239.</a></li><li><a class="nounderline abstract_t">Cervantes F, Alvarez-Larrán A, Domingo A, et al. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 2005; 129:771.</a></li><li><a class="nounderline abstract_t">Shimoda K, Shide K, Kamezaki K, et al. The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia: retrospective analysis of 39 patients in Japan. Int J Hematol 2007; 85:338.</a></li><li><a class="nounderline abstract_t">Cervantes F, Hernández-Boluda JC, Alvarez A, et al. Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica 2000; 85:595.</a></li><li><a class="nounderline abstract_t">Tefferi A, Silverstein MN. Recombinant human erythropoietin therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1994; 86:893.</a></li><li><a class="nounderline abstract_t">Rodríguez JN, Martino ML, Diéguez JC, Prados D. rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach. Haematologica 1998; 83:616.</a></li><li><a class="nounderline abstract_t">Mohr B, Herrmann R, Huhn D. Recombinant human erythropoietin in patients with myelodysplastic syndrome and myelofibrosis. Acta Haematol 1993; 90:65.</a></li><li><a class="nounderline abstract_t">Huang J, Tefferi A. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol 2009; 83:154.</a></li><li><a class="nounderline abstract_t">Aloe Spiriti M, Latagliata R, Avvisati G, et al. Erythropoietin treatment of idiopathic myelofibrosis. Haematologica 1993; 78:371.</a></li><li><a class="nounderline abstract_t">Cervantes F, Alvarez-Larrán A, Hernández-Boluda JC, et al. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 2004; 127:399.</a></li><li><a class="nounderline abstract_t">Cervantes F, Alvarez-Larrán A, Hernández-Boluda JC, et al. Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. Br J Haematol 2006; 134:184.</a></li><li><a class="nounderline abstract_t">Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006; 108:1158.</a></li><li><a class="nounderline abstract_t">Quintás-Cardama A, Kantarjian HM, Manshouri T, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 2009; 27:4760.</a></li><li><a class="nounderline abstract_t">Mesa RA, Yao X, Cripe LD, et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood 2010; 116:4436.</a></li><li><a class="nounderline abstract_t">Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 117:288.</a></li><li><a class="nounderline abstract_t">Mesa RA, Elliott MA, Schroeder G, Tefferi A. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc 2004; 79:883.</a></li><li><a class="nounderline abstract_t">Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003; 101:2534.</a></li><li><a class="nounderline abstract_t">Mesa RA, Kiladjian JJ, Catalano JV, et al. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis. J Clin Oncol 2017; 35:3844.</a></li><li><a class="nounderline abstract_t">Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol 2018; 4:652.</a></li><li><a class="nounderline abstract_t">Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366:787.</a></li><li><a class="nounderline abstract_t">Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366:799.</a></li><li><a class="nounderline abstract_t">Passamonti F, Caramazza D, Maffioli M. JAK inhibitor in CALR-mutant myelofibrosis. N Engl J Med 2014; 370:1168.</a></li><li><a class="nounderline abstract_t">Guglielmelli P, Biamonte F, Rotunno G, et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood 2014; 123:2157.</a></li><li class="breakAll">ruxolitinib. United States prescribing information. Revised July 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202192s006lbl.pdf (Accessed on August 04, 2014). (Accessed on January 03, 2019).</li><li><a class="nounderline abstract_t">Heine A, Held SA, Daecke SN, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 2013; 122:1192.</a></li><li><a class="nounderline abstract_t">Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest 2013; 143:1478.</a></li><li><a class="nounderline abstract_t">Caocci G, Murgia F, Podda L, et al. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia 2014; 28:225.</a></li><li><a class="nounderline abstract_t">Colomba C, Rubino R, Siracusa L, et al. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Res Notes 2012; 5:552.</a></li><li><a class="nounderline abstract_t">Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med 2013; 369:681.</a></li><li><a class="nounderline abstract_t">Wathes R, Moule S, Milojkovic D. Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med 2013; 369:197.</a></li><li><a class="nounderline abstract_t">Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood 2013; 122:3843.</a></li><li><a class="nounderline abstract_t">von Hofsten J, Johnsson Forsberg M, Zetterberg M. Cytomegalovirus Retinitis in a Patient Who Received Ruxolitinib. N Engl J Med 2016; 374:296.</a></li><li><a class="nounderline abstract_t">Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 2011; 365:1455.</a></li><li><a class="nounderline abstract_t">Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011; 86:1188.</a></li><li><a class="nounderline abstract_t">Dai T, Friedman EW, Barta SK. Ruxolitinib withdrawal syndrome leading to tumor lysis. J Clin Oncol 2013; 31:e430.</a></li><li><a class="nounderline abstract_t">Mollé N, Krichevsky S, Kermani P, et al. Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3. Blood 2020; 135:1062.</a></li><li><a class="nounderline abstract_t">Verstovsek S, Kantarjian HM, Estrov Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012; 120:1202.</a></li><li><a class="nounderline abstract_t">Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013; 122:4047.</a></li><li><a class="nounderline abstract_t">Passamonti F, Maffioli M, Cervantes F, et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood 2014; 123:1833.</a></li><li class="breakAll">fedratinib. US Food and Drug Administration. Revised August, 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf (Accessed on October 06, 2022).</li><li><a class="nounderline abstract_t">Pardanani A, Harrison C, Cortes JE, et al. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol 2015; 1:643.</a></li><li><a class="nounderline abstract_t">Singer JW, Al-Fayoumi S, Ma H, et al. Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor. J Exp Pharmacol 2016; 8:11.</a></li><li class="breakAll">pacritinib. United States prescribing information. Revised February 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208712s000lbl.pdf (Accessed on May 09, 2022).</li><li><a class="nounderline abstract_t">Sirhan S, Lasho TL, Hanson CA, et al. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Am J Hematol 2008; 83:363.</a></li><li><a class="nounderline abstract_t">Martínez-Trillos A, Gaya A, Maffioli M, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 2010; 89:1233.</a></li><li><a class="nounderline abstract_t">Tefferi A, Mesa RA, Nagorney DM, et al. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000; 95:2226.</a></li><li><a class="nounderline abstract_t">Pardanani A, Brown P, Neben-Wittich M, et al. Effective management of accelerated phase myelofibrosis with low-dose splenic radiotherapy. Am J Hematol 2010; 85:715.</a></li><li><a class="nounderline abstract_t">Mesa RA. How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood 2009; 113:5394.</a></li><li><a class="nounderline abstract_t">Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol 1998; 103:505.</a></li><li><a class="nounderline abstract_t">Steensma DP, Hook CC, Stafford SL, Tefferi A. Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 118:813.</a></li><li><a class="nounderline abstract_t">Koch CA, Li CY, Mesa RA, Tefferi A. Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc 2003; 78:1223.</a></li><li class="breakAll">Hoffman R. Agnogenic myeloid metaplasia (ch.63). In: Hematology: Basic Principles and Practice, 3rd ed, Hoffman R, Benz EJ Jr, Shattil SJ, et al. (Eds), Churchill Livingstone, New York 2000.</li><li><a class="nounderline abstract_t">Tefferi A, Jiménez T, Gray LA, et al. Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia. Eur J Haematol 2001; 66:37.</a></li><li><a class="nounderline abstract_t">Neben-Wittich MA, Brown PD, Tefferi A. Successful treatment of severe extremity pain in myelofibrosis with low-dose single-fraction radiation therapy. Am J Hematol 2010; 85:808.</a></li><li><a class="nounderline abstract_t">Cervantes F, Dupriez B, Passamonti F, et al. Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol 2012; 30:2981.</a></li><li><a class="nounderline abstract_t">Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113:2895.</a></li><li><a class="nounderline abstract_t">Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005; 105:973.</a></li><li><a class="nounderline abstract_t">Kennedy JA, Atenafu EG, Messner HA, et al. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. Blood 2013; 121:2725.</a></li><li><a class="nounderline abstract_t">Tam CS, Nussenzveig RM, Popat U, et al. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood 2008; 112:1628.</a></li><li><a class="nounderline abstract_t">Passamonti F, Rumi E, Arcaini L, et al. Leukemic transformation of polycythemia vera: a single center study of 23 patients. Cancer 2005; 104:1032.</a></li><li><a class="nounderline abstract_t">Noor SJ, Tan W, Wilding GE, et al. Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases. Leuk Res 2011; 35:608.</a></li><li><a class="nounderline abstract_t">Thepot S, Itzykson R, Seegers V, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 2010; 116:3735.</a></li><li><a class="nounderline abstract_t">Cherington C, Slack JL, Leis J, et al. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. Leuk Res 2012; 36:1147.</a></li><li><a class="nounderline abstract_t">Takagi S, Masuoka K, Uchida N, et al. Allogeneic Hematopoietic Cell Transplantation for Leukemic Transformation Preceded by Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Nationwide Survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2016; 22:2208.</a></li><li><a class="nounderline abstract_t">Mascarenhas J, Navada S, Malone A, et al. Therapeutic options for patients with myelofibrosis in blast phase. Leuk Res 2010; 34:1246.</a></li><li><a class="nounderline abstract_t">Eghtedar A, Verstovsek S, Estrov Z, et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood 2012; 119:4614.</a></li><li><a class="nounderline abstract_t">Mesa RA, Nagorney DS, Schwager S, et al. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006; 107:361.</a></li><li><a class="nounderline abstract_t">Barosi G, Ambrosetti A, Buratti A, et al. Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. Leukemia 1993; 7:200.</a></li><li><a class="nounderline abstract_t">Tefferi A, Silverstein MN, Li CY. 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia. Br J Haematol 1997; 99:352.</a></li><li><a class="nounderline abstract_t">Faoro LN, Tefferi A, Mesa RA. Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. Eur J Haematol 2005; 74:117.</a></li><li><a class="nounderline abstract_t">Verstovsek S, Gerds AT, Vannucchi AM, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet 2023; 401:269.</a></li><li><a class="nounderline abstract_t">Harrison CN, Vannucchi AM, Platzbecker U, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol 2018; 5:e73.</a></li><li><a class="nounderline abstract_t">Harrison CN, Schaap N, Vannucchi AM, et al. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Am J Hematol 2020; 95:594.</a></li></ol></div><div id="topicVersionRevision">Topic 4531 Version 111.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35767897" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35732831" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23071245" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29654267" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29708808" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20008785" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21149668" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37463903" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Nationwide prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to MYSEC-PM as a survival risk model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37463903" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Nationwide prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to MYSEC-PM as a survival risk model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26293647" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9326204" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. French Society of Bone Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12920019" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Allogeneic hematopoietic stem cell transplantation for myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9423812" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8750263" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Allogeneic bone marrow transplantation for primary myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1482667" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Allogeneic bone marrow transplantation for primary myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12911046" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hematopoietic cell transplantation for adult patients with myelodysplastic syndromes and myeloproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10216077" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, SociétéFrançaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21042309" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2375922" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25784679" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34536293" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : 2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26371371" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33911203" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34152630" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21323890" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34023851" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33767402" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29791053" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24569777" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26726940" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26493563" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34581764" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33064301" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28263921" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The Impact of Splenectomy in Myelofibrosis Patients before Allogeneic Hematopoietic Stem Cell Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33108024" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36624162" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Splenic irradiation prior to allogeneic hematopoietic cell transplantation for patients with myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31284069" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24161923" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19812383" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24963042" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21133885" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the SociétéFrançaise de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16972981" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11877308" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12437657" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15725091" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15671439" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19718055" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20489052" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21552298" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22280409" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17133423" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18685610" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24389309" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17085309" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21415963" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Outcome of allogeneic stem cell transplantation following reduced-intensity conditioninig regimen in patients with idiopathic myelofibrosis: the g.I.T.m.o. Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19786111" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26970380" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19879949" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Outcome of transplantation for myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30408564" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8541560" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8948661" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15953003" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17483079" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia: retrospective analysis of 39 patients in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10870115" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Danazol treatment of idiopathic myelofibrosis with severe anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7918092" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Recombinant human erythropoietin therapy in patients with myelofibrosis with myeloid metaplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9718866" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8285020" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Recombinant human erythropoietin in patients with myelodysplastic syndrome and myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19366369" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8175031" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Erythropoietin treatment of idiopathic myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15521916" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16740139" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16609064" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Lenalidomide therapy in myelofibrosis with myeloid metaplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19720904" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20651074" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11972510" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Thalidomide treatment in myelofibrosis with myeloid metaplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15244384" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12517815" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28930494" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29522138" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22375970" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22375971" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24645956" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : JAK inhibitor in CALR-mutant myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24458439" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24458439" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23770777" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23648912" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23929216" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23039051" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23944322" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Bilateral toxoplasmosis retinitis associated with ruxolitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23841743" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Progressive multifocal leukoencephalopathy associated with ruxolitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24288410" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26789901" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Cytomegalovirus Retinitis in a Patient Who Received Ruxolitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21995409" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Long-term outcome of treatment with ruxolitinib in myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22034658" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23752116" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Ruxolitinib withdrawal syndrome leading to tumor lysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32047890" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22718840" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24174625" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24443442" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24443442" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26181658" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27574472" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27574472" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18266209" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20567824" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10733489" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20661915" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Effective management of accelerated phase myelofibrosis with low-dose splenic radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19332765" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : How I treat symptomatic splenomegaly in patients with myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9827926" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12181050" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14531481" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14531481" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11168506" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20799357" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Successful treatment of severe extremity pain in myelofibrosis with low-dose single-fraction radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22826273" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Improving survival trends in primary myelofibrosis: an international study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18988864" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15388582" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23361905" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18566326" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16047334" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Leukemic transformation of polycythemia vera: a single center study of 23 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20727590" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664061" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22578777" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27667010" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Allogeneic Hematopoietic Cell Transplantation for Leukemic Transformation Preceded by Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Nationwide Survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20627294" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Therapeutic options for patients with myelofibrosis in blast phase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22422826" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16770787" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8426474" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9375753" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15654901" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36709073" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29275119" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32129512" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
